Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pralsetinib - Blueprint Medicines

Next Previous
Search
Drug Profile

Pralsetinib - Blueprint Medicines

Alternative Names: BLU-667; CS 3009; GAVRETO; Gavreto; Pratinib; Pujihua; RG 6396

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; CStone Pharmaceuticals; Roche
  • Class Amides; Amines; Antineoplastics; Cyclohexanes; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Thyroid cancer
  • Phase II Solid tumours

Most Recent Events

  • 21 Feb 2025 Hoffmann-La Roche completes phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, First-line therapy, Metastatic disease) in Turkey, Sweden, Switzerland, Panama, Mexico, Japan, Ireland, Costa Rica, Brazil, Australia, Argentina, Belgium, Finland, France, Germany, Czech Republic, Italy, Norway, Poland, Portugal, Netherlands, Spain, Taiwan, United Kingdom, South Korea, USA (PO) (NCT04222972) (EudraCT2019-002463-10)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria (PO, Capsule)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Georgia (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top